Bristol Myers Squibb announced that the US Food and Drug Administration (FDA) had accepted the supplemental New Drug Application (sNDA) for Augtyro (repotrectinib) for the treatment of adult and pediatric patients 12 years of age
Trade and Investment Queensland (TIQ), the dedicated business arm of the Queensland Government and the global sponsor of Bio Asia 2024, will be held in Hyderabad from 26-28 February.
Getinge, a global leader in medical technology, has announced the launch of its new Servo-c machine in the Indian market. Servo-c is designed to meet the diverse respiratory needs of pediatric and adult patients and provides a lung-preserving medical
Caliway Biopharmaceuticals (Caliway) announced that the US Food and Drug Administration (FDA) has granted Fast Track designation to study CBL-514 for treating Dercombe's disease. CBL-514 is a lipolytic injection that can reduce local subcutaneous
Pharus Diagnostics, an innovative healthcare company based in Hsinchu, Taiwan, announced an exclusive global license agreement with the City of Hope, one of the largest cancer research and treatment organizations in the United States
Glenmark Pharmaceuticals Ltd. (Glenmark), a research-led global pharmaceutical company, has announced financial results for the third quarter ended December 31, 2023.
Lupine Limited (Lupin), a global pharmaceutical company, announced the launch of Ganirelix Acetate Injection, 250 mcg / 0.5 mL, single-dose prefilled syringe, approved by the United States Food and Drug Administration (FDA).
The Central Drugs Standard Control Organization (CDSCO) has released the final version of its regulatory guidelines for sampling medicines, cosmetics and medical devices by central drug inspectors to simplify and streamline sampling procedures
Cipla said it has partnered with CSIR-Central Drug Research Institute to foster a novel ophthalmic detailing for contagious keratitis mutually. The coordinated effort expects to use the consolidated mastery and assets of the two associations to...
Biogen Inc. announced the European Commission (EC) has authorized Skyclarys (omaveloxolone) for the treatment of Friedreich’s ataxia (FA) in adults and adolescents aged 16 years and older. Skyclarys is the first treatment approved within the...
, CDSCO.jpg)
